121 related articles for article (PubMed ID: 3667164)
1. Phase II evaluation of bisantrene hydrochloride in refractory malignant melanoma. A Southwest Oncology Group Study.
Alberts DS; Mason-Liddil N; Green SJ; Cowan JD; Fletcher WS; Neilan B; Guy JT; Epstein RB
Invest New Drugs; 1987; 5(3):289-92. PubMed ID: 3667164
[TBL] [Abstract][Full Text] [Related]
2. Phase II trial of Bisantrene for metastatic melanoma: an Illinois cancer council study.
Stiff PJ; Sweet D; Kilton LJ; Johnson CM; Muntean B; Blough RR
Med Pediatr Oncol; 1991; 19(2):126-8. PubMed ID: 2011097
[TBL] [Abstract][Full Text] [Related]
3. Phase II trial of bisantrene in non-small cell lung cancer.
Miller TP; Ahmann FR; Mackel C; Greenberg BR; Alberts DS
Invest New Drugs; 1985; 3(4):393-5. PubMed ID: 4086247
[TBL] [Abstract][Full Text] [Related]
4. Randomized trial of doxorubicin, bisantrene, and mitoxantrone in advanced breast cancer: a Southwest Oncology Group study.
Cowan JD; Neidhart J; McClure S; Coltman CA; Gumbart C; Martino S; Hutchins LF; Stephens RL; Vaughan CB; Osborne CK
J Natl Cancer Inst; 1991 Aug; 83(15):1077-84. PubMed ID: 1875415
[TBL] [Abstract][Full Text] [Related]
5. Phase II evaluation of bisantrene in acute leukemia. A Southwest Oncology Group Study.
Mills GM; Dahlberg S; Cowan J; Neilan BA; Gumbart CH; Hussein K; Coltman CA
Am J Clin Oncol; 1989 Dec; 12(6):507-10. PubMed ID: 2589232
[TBL] [Abstract][Full Text] [Related]
6. Chemotherapy in metastatic melanoma: phase II studies of amsacrine, mitoxantrone and bisantrene.
Coates AS; Bishop J; Mann GJ; Raghavan D
Eur J Cancer Clin Oncol; 1986 Jan; 22(1):97-100. PubMed ID: 3754214
[TBL] [Abstract][Full Text] [Related]
7. Phase I clinical investigation of 9,10-anthracenedicarboxaldehyde bis[(4,5-dihydro-1H-imidazol-2-yl)hydrazone] dihydrochloride with correlative in vitro human tumor clonogenic assay.
Alberts DS; Mackel C; Pocelinko R; Salmon SE
Cancer Res; 1982 Mar; 42(3):1170-5. PubMed ID: 7037174
[TBL] [Abstract][Full Text] [Related]
8. A phase II evaluation of esorubicin in ovarian cancer. A Southwest Oncology Group study.
Alberts DS; Mason-Liddil N; Stock-Novack D; O'Toole RV; Abbott TM; Salmon SE
Am J Clin Oncol; 1992 Apr; 15(2):146-9. PubMed ID: 1553903
[TBL] [Abstract][Full Text] [Related]
9. Bisantrene hydrochloride in gastric adenocarcinoma: a Southwest Oncology Group Study.
Panettiere FJ; Jones SE; Oishi N; Eyre HJ; O'Bryan RM; Andes WA; Taylor SA; Grozea PN
Med Pediatr Oncol; 1986; 14(2):78-80. PubMed ID: 3713640
[TBL] [Abstract][Full Text] [Related]
10. A randomized trial of doxorubicin, mitoxantrone and bisantrene in advanced breast cancer (a South West Oncology Group Study).
Cowan JD; Osborne CK; Neidhart JA; Von Hoff DD; Constanzi JJ; Vaughn CB
Invest New Drugs; 1985; 3(2):149-52. PubMed ID: 3894277
[TBL] [Abstract][Full Text] [Related]
11. Bisantrene, an active drug in patients with advanced breast cancer.
Osborne CK; Von Hoff DD; Cowan JD; Sandbach J
Cancer Treat Rep; 1984 Feb; 68(2):357-60. PubMed ID: 6697324
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial of bisantrene in patients with intermediate and high grade diffuse non-Hodgkin's lymphomas.
Miller TP; Jones SE; Alberts DS; Mackel C
Invest New Drugs; 1984; 2(1):75-7. PubMed ID: 6469502
[TBL] [Abstract][Full Text] [Related]
13. A phase I and pharmacokinetic comparison of hepatic arterial and peripheral vein infusions of bisantrene for liver cancer.
Weiss GR; Hersh M; Kuhn JG; Ludden TM; von Hoff DD; Kisner DL; Pirtle TE
Cancer Chemother Pharmacol; 1985; 15(2):144-8. PubMed ID: 4017163
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of bisantrene in patients with metastatic melanoma.
Mackel C; Meyskens FL; Alberts DS
Cancer Treat Rep; 1986 Aug; 70(8):1037-8. PubMed ID: 3731151
[No Abstract] [Full Text] [Related]
15. Phase I study of bisantrene in acute nonlymphoblastic leukemia.
Marty M; Ferme C; Gisselbrecht C; Guy H; Clark MJ; Bancillon A; Boiron M
Cancer Treat Rep; 1985 Jun; 69(6):703-5. PubMed ID: 4016773
[TBL] [Abstract][Full Text] [Related]
16. Experimental studies and phase II trial of bisantrene in advanced urothelial malignancies.
Scher HI; Ahmed T; Yagoda A; Kyriazis AP; Watson RC
Cancer Invest; 1985; 3(2):123-7. PubMed ID: 3995377
[TBL] [Abstract][Full Text] [Related]
17. A phase II study of bisantrene in malignant lymphomas. A Southwest Oncology Group Study.
Miller TP; Cowan JD; Neilan BA; Jones SE
Cancer Chemother Pharmacol; 1986; 16(1):67-9. PubMed ID: 3940222
[TBL] [Abstract][Full Text] [Related]
18. Bisantrene (NSC 337766) (CL 216,942) in advanced breast cancer. A cancer and leukemia group B study.
Forastiere AA; Perry MC; Hughes AK; Wood WC
Cancer Chemother Pharmacol; 1984; 13(3):226-9. PubMed ID: 6488443
[TBL] [Abstract][Full Text] [Related]
19. Phase II trial of bisantrene in previously treated patients with ovarian carcinoma: a Southwest Oncology Group Study.
Cowan JD; Surwit EA; Alberts DS; Boutselis JG; Neilan BA
Cancer Treat Rep; 1986 Mar; 70(3):423-4. PubMed ID: 3955558
[No Abstract] [Full Text] [Related]
20. Activity of bisantrene in refractory lymphoma.
McLaughlin P; Cabanillas F; Hagemeister FB; Velasquez WS
Cancer Treat Rep; 1987 Jun; 71(6):631-3. PubMed ID: 3581102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
